126 related articles for article (PubMed ID: 24919263)
21. Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells.
Hartomo TB; Kozaki A; Hasegawa D; Van Huyen Pham T; Yamamoto N; Saitoh A; Ishida T; Kawasaki K; Kosaka Y; Ohashi H; Yamamoto T; Morikawa S; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Iijima K; Matsuo M; Nishio H; Nishimura N
Oncol Rep; 2013 Apr; 29(4):1629-36. PubMed ID: 23417100
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma.
Parareda A; Gallego S; Roma J; Llort A; Sábado C; Gros L; De Toledo JS
Oncol Rep; 2005 Oct; 14(4):1021-7. PubMed ID: 16142367
[TBL] [Abstract][Full Text] [Related]
23. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
24. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
[TBL] [Abstract][Full Text] [Related]
25. Presence of differentiating neuroblasts in bone marrow is a favorable prognostic factor for bone marrow metastatic neuroblastoma at diagnosis.
Park SH; Kim S; Park CJ; Jang S; Chi HS; Koh KN; Im HJ; Seo JJ
Ann Lab Med; 2013 Mar; 33(2):89-96. PubMed ID: 23483759
[TBL] [Abstract][Full Text] [Related]
26. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma.
Kuroda T; Morikawa N; Matsuoka K; Fujino A; Honna T; Nakagawa A; Kumagai M; Masaki H; Saeki M
J Pediatr Surg; 2008 Dec; 43(12):2182-5. PubMed ID: 19040931
[TBL] [Abstract][Full Text] [Related]
28. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
[TBL] [Abstract][Full Text] [Related]
29. Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.
Asgharzadeh S; Marachelian A; Villablanca JG; Liu WY; Kennedy R; Sposto R; Naranjo A; Tenney S; Yu AL; Ozkaynak MF; Sondel PM; Park JR; Seeger RC
Pediatr Blood Cancer; 2022 Sep; 69(9):e29719. PubMed ID: 35441784
[TBL] [Abstract][Full Text] [Related]
30. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease.
Simon T; Hero B; Bongartz R; Schmidt M; Müller RP; Berthold F
Strahlenther Onkol; 2006 Jul; 182(7):389-94. PubMed ID: 16826357
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic utility of PHOX2B in primary and treated neuroblastoma and in neuroblastoma metastatic to the bone marrow.
Hata JL; Correa H; Krishnan C; Esbenshade AJ; Black JO; Chung DH; Mobley BC
Arch Pathol Lab Med; 2015 Apr; 139(4):543-6. PubMed ID: 25822764
[TBL] [Abstract][Full Text] [Related]
32. Detection of residual neuroblastoma cells in bone marrow: comparison of flow cytometry with immunocytochemistry.
Swerts K; De Moerloose B; Dhooge C; Brichard B; Benoit Y; Laureys G; Philippé J
Cytometry B Clin Cytom; 2004 Sep; 61(1):9-19. PubMed ID: 15351977
[TBL] [Abstract][Full Text] [Related]
33. Measurement of tyrosine hydroxylase transcripts in bone marrow using biopsied tissue instead of aspirates for neuroblastoma.
Lee ST; Suh YL; Ko YH; Ki CS; Sung KW; Kim HJ; Kim JW; Kim SH; Chueh H; Lee SH; Yoo KH; Koo HH
Pediatr Blood Cancer; 2010 Aug; 55(2):273-8. PubMed ID: 20582938
[TBL] [Abstract][Full Text] [Related]
34. PHOX2B immunolabeling: a novel tool for the diagnosis of undifferentiated neuroblastomas among childhood small round blue-cell tumors.
Bielle F; Fréneaux P; Jeanne-Pasquier C; Maran-Gonzalez A; Rousseau A; Lamant L; Paris R; Pierron G; Nicolas AV; Sastre-Garau X; Delattre O; Bourdeaut F; Peuchmaur M
Am J Surg Pathol; 2012 Aug; 36(8):1141-9. PubMed ID: 22790854
[TBL] [Abstract][Full Text] [Related]
35. Neuroblastoma and bone metastases: clinical significance and prognostic value of Dickkopf 1 plasma levels.
Granchi D; Corrias MV; Garaventa A; Baglìo SR; Cangemi G; Carlini B; Paolucci P; Giunti A; Baldini N
Bone; 2011 Jan; 48(1):152-9. PubMed ID: 20603237
[TBL] [Abstract][Full Text] [Related]
36. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.
Lambooy LH; Gidding CE; van den Heuvel LP; Hulsbergen-van de Kaa CA; Ligtenberg M; Bökkerink JP; De Abreu RA
Clin Cancer Res; 2003 Feb; 9(2):812-9. PubMed ID: 12576454
[TBL] [Abstract][Full Text] [Related]
37. Limitations in the ability of NB84 to detect metastatic neuroblastoma cells in bone marrow.
Bomken SN; Redfern K; Wood KM; Reid MM; Tweddle DA
J Clin Pathol; 2006 Sep; 59(9):927-9. PubMed ID: 16565222
[TBL] [Abstract][Full Text] [Related]
38. The prognostic significance of vanillylmandellic acid in neuroblastoma.
Aydin GB; Kutluk MT; Yalcin B; Varan A; Akyuz C; Buyukpamukcu M
Pediatr Hematol Oncol; 2010 Sep; 27(6):435-48. PubMed ID: 20578806
[TBL] [Abstract][Full Text] [Related]
39. Improving Detection of Metastatic Neuroblastoma in Bone Marrow Core Biopsies: A Proposed Immunohistochemical Approach.
Parsons LN; Gheorghe G; Yan K; Simpson P; Jarzembowski JA
Pediatr Dev Pathol; 2016; 19(3):230-6. PubMed ID: 26491958
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.
Cheung NK; Ostrovnaya I; Kuk D; Cheung IY
J Clin Oncol; 2015 Mar; 33(7):755-63. PubMed ID: 25559819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
